Premium
Treatment with GnRH agonists before myomectomy and the risk of short‐term myoma recurrence
Author(s) -
FEDELE LUIGI,
VERCELLINI PAOLO,
BIANCHI STEFANO,
BRIOSCHI DIANA,
DORTA MILENA
Publication year - 1990
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1990.tb01824.x
Subject(s) - medicine , buserelin , myoma , surgery , uterine myomectomy , blood loss , leiomyoma , uterus , agonist , receptor
Summary. Twenty‐four women with symptomatic multiple uterine myomas were allocated randomly to treatment with buserelin, 1200μg/day intranasally, for 3 months followed by myomectomy ( n = 8) or to immediate myomectomy ( n = 16). Pre‐operative treatment with buserelin reduced the mean uterine volume from 432 (SD 165) to 242 (SD 82) ml ( P < 0.01) but intra‐operative blood loss and postoperative morbidity were not significantly less in this group. Six months after operation, pelvic examination was normal in all the patients. However, ultrasonography with transvaginal probe demonstrated the presence of myomas of < 1.5 cm in five women (63%) treated pre‐operatively with the analogue and in two women (13%) who underwent immediate surgery (P < 0.05). Induction of a period of hypo‐oestrogenism before myomectomy seems to favour short‐term recurrence of uterine myomas, limiting the efficacy of surgery.